Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

George D. Demetri, Paolo G. Casali, Martin E. Blackstein et al.|The Lancet|2012

Cited by 1.4k